Merck buys Afferent Pharmaceuticals for $500m

10-06-2016

Merck buys Afferent Pharmaceuticals for $500m

Maksym Dykha / Shutterstock.com

Pharmaceutical company Merck has bought Afferent Pharmaceuticals in a deal worth $500 million.  


Merck, Afferent Pharmaceuticals, AF-219, idiopathic pulmonary fibrosis, refractory, Roger Perlmutter, Kathleen Sereda Glaub,

LSIPR